Latest Commercialization News

Resources & Energy Group Limited has raised $2 million to fund drilling and production expansion at its East Menzies Gold Project, following a year of significant operational milestones.

Orezone Gold Corporation has successfully completed commissioning of its Bomboré hard rock expansion, achieving first gold production and setting the stage for a significant increase in output next year.

EV Resources reports exceptional antimony recovery at its Los Lirios project using a simplified gravity process, paving the way for a lower-cost, accelerated development timeline.

CONNEQT Health’s Pulse arterial health monitor sales have outpaced expectations with over 200% growth in the December quarter, driven by efficient marketing and early subscription uptake.

Gold Hydrogen Limited’s latest drilling at Ramsay 4 confirms significant natural hydrogen and helium formations, setting the stage for critical flow testing in early 2026 to assess commercial viability.

3D Energi has raised $14.5 million through a well-supported placement to fund critical drilling and testing activities in the Otway Basin, aiming to unlock new gas reserves for Australia's East Coast market.

American Rare Earths has successfully produced mixed rare earth oxides from Halleck Creek ore, marking a pivotal technical breakthrough in its mineral processing program. This achievement advances the project closer to commercial viability amid growing demand for critical minerals.

Emyria has secured its first Empax clinic in Victoria, marking a significant step in its multi-state expansion and validating its scalable, reimbursed national mental health platform.

Pacific Lime and Cement Limited has secured a strategic advisory partnership with the International Finance Corporation to advance Papua New Guinea’s inaugural vertically integrated clinker and cement production project.

Entropy Neurodynamics has successfully completed dosing the first patient in its TRP-8803 clinical trial for Binge Eating Disorder, marking a key milestone with controlled psychedelic infusion and safety clearance. Top-line results are expected in early 2026.

Adherium Limited reports a remarkable 103% quarter-on-quarter growth in Remote Patient Monitoring subscription revenues for Q2 FY26, driven by strong device shipment momentum and strategic operational changes.

Immutep Limited reports robust progress in its pivotal Phase III TACTI-004 trial for advanced non-small cell lung cancer, with over 120 clinical sites activated across 27 countries including the US. Patient enrolment has reached 38% of the target, keeping key milestones on track.